骨桥蛋白在慢阻肺和非小细胞肺癌中的作用

罗 玉巧1, 徐 一凡1, 魏 婷婷2, 郎 克2, 李 鸿儒2, 宁 馨仪2, 王 晓岑2, 杨 冬2
1、上海理工大学　健康科学与工程学院
2、复旦大学　中山医院

摘要


骨桥蛋白是一种高度磷酸化的糖蛋白，广泛存在于多种组织和器官中。近年来的研究表明，骨桥蛋白在肺
部疾病中发挥着重要作用。在慢性阻塞性肺疾病中，骨桥蛋白的异常表达与肺部炎症、气道重塑和肺气肿等病理过
程密切相关。在非小细胞肺癌中，骨桥蛋白的过度表达与肿瘤的增殖、侵袭和转移密切相关。因此，骨桥蛋白在慢
性阻塞性肺疾病和非小细胞肺癌中的关键作用值得深入研究。本文将对骨桥蛋白在这两种疾病中的关键作用进行综
述，包括其在慢性阻塞性肺疾病的发病机制中的作用以及非小细胞肺癌发生、发展和转移中的作用机制；探讨骨桥
蛋白在这两种疾病中的潜在治疗靶点和临床应用前景。

关键词


骨桥蛋白；慢性阻塞性肺疾病；非小细胞肺癌；作用机制；治疗靶点

全文:

PDF


参考


[1]Lee S J, Kim S H, Kim W, et al. Increased plasma

osteopontin in frequent exacerbator and acute exacerbation of

COPD[J]. The clinical respiratory journal, 2014, 8(3): 305-

311.

[2]Papaporfyriou A, Loukides S, Kostikas K, et al.

Increased levels of osteopontin in sputum supernatant in

patients with COPD[J]. Chest, 2014, 146(4): 951-958.

[3]Sun B, Jian Y O U, Yue L I, et al. Osteopontin

knockdown suppresses non-small cell lung cancer cell

invasion and metastasis[J]. Chinese medical journal, 2013,

126(9): 1683-1688.

[4]Miao T, Du L, et al. High expression of SPP1 in

patients with chronic obstructive pulmonary disease (COPD)

is correlated with increased risk of lung cancer[J]. FEBS open

bio, 2021, 11(4): 1237-1249.

[5]Gimba E R, Tilli T M. Human osteopontin splicing

isoforms: known roles, potential clinical applications and

activated signaling pathways[J]. Cancer letters, 2013, 331(1):

11-17.

[6]Hou J, Ji J, Chen X, et al. Alveolar epithelial

cell‐derived Sonic hedgehog promotes pulmonary

fibrosis through OPN‐dependent alternative macrophage

activation[J]. The FEBS Journal, 2021, 288(11): 3530-3546.

[7]Moorman H R, Poschel D, Klement J D, et al.

Osteopontin: a key regulator of tumor progression and

immunomodulation[J]. Cancers, 2020, 12(11): 3379.

[8]Dong J, Ma Q. Osteopontin enhances multi-walled

carbon nanotube-triggered lung fibrosis by promoting TGF-

β1 activation and myofibroblast differentiation[J]. Particle

and fibre toxicology, 2017, 14: 1-21.

[9]Wai P Y, Kuo P C. The role of osteopontin in tumor

metastasis[J]. Journal of Surgical Research, 2004, 121(2): 228-

241.

[10]Fong Y C, Liu S C, Huang C Y, et al. Osteopontin

increases lung cancer cells migration via activation of the

αvβ3 integrin/FAK/Akt and NF-κB-dependent

pathway[J]. Lung cancer, 2009, 64(3): 263-270.

[11]Zhang M, Sun Y, Zhang Y, et al. Lipopolysaccharide

and lipoteichoic acid regulate the PI3K/AKT pathway

through osteopontin/integrin β3 to promote malignant

progression of non-small cell lung cancer[J]. Journal of

Thoracic Disease, 2023, 15(1): 168.Weber G F, Lett GS,

Haubein NC.

[12]Zhang J, Li H, Wu Q, et al. Tumoral NOX4

recruits M2 tumor-associated macrophages via ROS/PI3K

signaling-dependent various cytokine production to promote

NSCLC growth[J]. Redox biology, 2019, 22: 101116.

[13]Gottschling S, Granzow M, Kuner R, et al.

Mesenchymal stem cells in non-small cell lung cancer—

different from others? Insights from comparative molecular

and functional analyses[J]. Lung cancer, 2013, 80(1): 19-29.

[14]Maneechotesuwan K, Kasetsinsombat K,

Wongkajornsilp A, et al. Simvastatin up-regulates adenosine

deaminase and suppresses osteopontin expression in COPD

patients through an IL-13-dependent mechanism[J].

Respiratory research, 2016, 17: 1-11.


Refbacks

  • 当前没有refback。